Printer Friendly

Recent Report Provides a Compilation of Current Active Projects in Research and Development of Novel GLP-1 Analogs and GLP-1 Receptor Agonists.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/a64686/competitor_analysi) has announced the addition of the "Competitor Analysis: GLP-1 Receptor Agonists" report to their offering.

The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Analogs as of November 2008 provides a competitor analysis in the development pipeline of novel GLP-1 Analogs and GLP-1 receptor agonists for the treatment of type 2 diabetes.

Binding of glucagon-like peptide-1 (GLP-1) analogs or agonists to the GLP receptor induces insulin secretion from pancreatic beta cells. Exendin (Byetta) is the first representative of this new class of incretin mimetics, first approved in 2005 for the treatment of type 2 diabetes. Byetta sales in the first nine months of 2008 increased by 22 % to US$ 565 million (vs 9-month period of previous year). While Byetta requires twice-daily subcutaneous injections, closest competitor GLP-1 analogs already filed for registration or in phase III, offer once-daily SC dosing and appear to be more effective in head-to-head comparison. Second generation GLP-1 analogs allow less frequent SC administration due to drug delivery, pegylation or genetic engineering technologies.

At least seven different long-acting GLP-1 analog molecules are currently in clinical development and a further seven are in advanced preclinical stages. A third generation of GLP-1 analogs and GLP-1 receptor agonists with oral administration is emerging. The first two orally delivered GLP-1 mimetics (one analog, one agonist) are already undergoing clinical development, and at least eight different compounds are in preclinical R&D. Traditional drug delivery solutions for the non-injectable administration of GLP-1 mimetics, such as inhalation or nasal administration, are a minority approach.

Key Topics Covered:

The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,

- Target / Mechanism of Action,

- Class of Compound,

- Company,

- Product Category,

- Indication,

- R&D Stage and

- additional comments with a hyperlink leading to the source of information.

Index

- GLP-1 Analogs with Daily Injection

- Long-Acting Injectable GLP-1 Analogs

- Oral GLP-1 Analogs

- Other Non-Injectable GLP-1 Analogs

- GLP-1 Analogs for Other Indications

- Corporate GLP-1 Analog R&D Pipelines

Some of the Companies mentioned:

- Addex Pharmaceuticals

- Arisgen

- ConjuChem

- Dong-A Pharmaceutical

- Eli Lilly

- Emisphere Technologies

- MDRNA (ex Nastech Pharmaceuticals)

- Modigene

- Novo Nordisk

- Pfizer

- Sanofi-Aventis

- TransTech Pharma

- Unigene

For more information visit http://www.researchandmarkets.com/research/a64686/competitor_analysi
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 10, 2008
Words:392
Previous Article:IP-PRIME's Market Leadership Reinforced with Sixty Plus Telco Contracts and Commercial Rollouts in Two Dozen Communities.
Next Article:J.S. Hovnanian & Sons Broke Records At The 2008 MAME Awards.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters